ABIVAX Société Anonyme Past Earnings Performance
Past criteria checks 0/6
ABIVAX Société Anonyme's earnings have been declining at an average annual rate of -36.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 54.7% per year.
Key information
-36.5%
Earnings growth rate
-10.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 54.7% |
| Return on equity | -75.4% |
| Net Margin | -3,288.2% |
| Next Earnings Update | 09 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ABIVAX Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -148 | 29 | 103 |
| 30 Sep 23 | 4 | -120 | 21 | 84 |
| 30 Jun 23 | 0 | -92 | 12 | 66 |
| 31 Mar 23 | 0 | -76 | 10 | 57 |
| 31 Dec 22 | 4 | -61 | 7 | 48 |
| 30 Sep 22 | 8 | -54 | 6 | 56 |
| 30 Jun 22 | 2 | -47 | 4 | 63 |
| 31 Mar 22 | 1 | -45 | 5 | 55 |
| 31 Dec 21 | 4 | -42 | 6 | 48 |
| 30 Sep 21 | 0 | -41 | 6 | 24 |
| 30 Jun 21 | 0 | -39 | 6 | 0 |
| 31 Mar 21 | 0 | -38 | 6 | 0 |
| 31 Dec 20 | 0 | -38 | 6 | 0 |
| 30 Sep 20 | 0 | -35 | 5 | 0 |
| 30 Jun 20 | 0 | -32 | 5 | 0 |
| 31 Mar 20 | 0 | -31 | 5 | 0 |
| 31 Dec 19 | 0 | -31 | 5 | 0 |
| 30 Sep 19 | 0 | -27 | 5 | 0 |
| 30 Jun 19 | 0 | -23 | 5 | 0 |
| 31 Mar 19 | 1 | -19 | 5 | 0 |
| 31 Dec 18 | 1 | -16 | 4 | 0 |
| 30 Sep 18 | 1 | -14 | 4 | 0 |
| 30 Jun 18 | 1 | -13 | 4 | 0 |
| 31 Mar 18 | 1 | -12 | 4 | 0 |
| 31 Dec 17 | 0 | -11 | 4 | 0 |
| 30 Sep 17 | 0 | -11 | 4 | 0 |
| 30 Jun 17 | 0 | -12 | 4 | 0 |
| 31 Mar 17 | 0 | -13 | 4 | 0 |
| 31 Dec 16 | 0 | -14 | 4 | 0 |
| 30 Sep 16 | 0 | -16 | 4 | 0 |
| 30 Jun 16 | 0 | -17 | 4 | 0 |
| 31 Mar 16 | 0 | -17 | 4 | 0 |
| 31 Dec 15 | 0 | -16 | 3 | 0 |
| 30 Sep 15 | 0 | -14 | 3 | 0 |
| 30 Jun 15 | 0 | -12 | 3 | 0 |
| 31 Mar 15 | 0 | -8 | 2 | 0 |
| 31 Dec 14 | 0 | -5 | 2 | 0 |
Quality Earnings: 2X1 is currently unprofitable.
Growing Profit Margin: 2X1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2X1 is unprofitable, and losses have increased over the past 5 years at a rate of 36.5% per year.
Accelerating Growth: Unable to compare 2X1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2X1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 2X1 has a negative Return on Equity (-75.37%), as it is currently unprofitable.